mAbs 2014; 6 (2):523-532). Cusatuzumab is currently being evaluated in patients ... Cusatuzumab is a first-in-class high-affinity humanized monoclonal antibody targeting CD70, an immune checkpoint ...
SAN FRANCISCO and KIGALI, Rwanda, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bio Usawa and the Rwanda Development Board have partnered to establish Rwanda’s first manufacturing plant for affordable treatments ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...